KDR and neoplasm: Apatinib is another type of TKIs that inhibits the formation of tyrosine kinase and inhibits the neoangiogenesis of tumor tissue through highly selective competition for ATP binding sites of VEGFR-2 in cells, so as to achieve the purpose of anti-tumor.